Zobrazeno 1 - 10
of 54
pro vyhledávání: '"David Noyes"'
Autor:
AGM Mostofa, Allison Distler, Mark B. Meads, Eva Sahakian, John J. Powers, Alexandra Achille, David Noyes, Gabriela Wright, Bin Fang, Victoria Izumi, John Koomen, Rupal Rampakrishnan, Tuan P. Nguyen, Gabriel De Avila, Ariosto S. Silva, Praneeth Sudalagunta, Rafael Renatino Canevarolo, Maria D. Coelho Siqueira Silva, Raghunandan Reddy Alugubelli, Hongyue A. Dai, Amit Kulkarni, William S. Dalton, Oliver A. Hampton, Eric A. Welsh, Jamie K. Teer, Alexandre Tungesvik, Kenneth L. Wright, Javier Pinilla-Ibarz, Eduardo M. Sotomayor, Kenneth H. Shain, Jason Brayer
Publikováno v:
JCI Insight, Vol 6, Iss 24 (2021)
The clinical utility of histone/protein deacetylase (HDAC) inhibitors in combinatorial regimens with proteasome inhibitors for patients with relapsed and refractory multiple myeloma (MM) is often limited by excessive toxicity due to HDAC inhibitor pr
Externí odkaz:
https://doaj.org/article/7fe4645c54d74f3db9e69957840e8738
Autor:
David Noyes, Chao Wang, Scott Antonia, Jose Conejo-Garcia, Bin Fang, John Koomen, Jamie Teer, Jiqiang Yao, Carmen Anadon, Ana Landin, Xiaoqing Yu, Dongliang Du, Zachary Thompson, Sungjune Kim, Dung-Tsa Chen, Eric Haura, Ben Creelan
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/b82381bc23544c179ad3a9adddf575ab
Autor:
Melanie Mediavilla-Varela, Julio Castro, Alberto Chiappori, David Noyes, Dalia C. Hernandez, Bertrand Allard, John Stagg, Scott J. Antonia
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 19, Iss 7, Pp 530-536 (2017)
BACKGROUND: Therapeutic strategies targeting immune checkpoint proteins have led to significant responses in patients with various tumor types. The success of these studies has led to the development of various antibodies/inhibitors for the different
Externí odkaz:
https://doaj.org/article/1e09019f9dbb4076babae1b44dda43c7
Autor:
Keiran S.M. Smalley, Paulo C. Rodriguez, Yian A. Chen, Christin E. Burd, Uwe Rix, Kenneth Y. Tsai, Kimberly T. Nguyen, Zeynep Eroglu, Dennis O. Adeegbe, David Noyes, Peter A. Forsyth, Brian J. Czerniecki, Vinayak Palve, Derek R. Duckett, Inna Smalley, Michael A. Davies, Eslam Mohamed, Jiannong Li, Zhihua Chen, Manali S. Phadke
Immunotherapy (IT) and targeted therapy (TT) are both effective against melanoma, but their combination is frequently toxic. Here, we investigated whether the sequence of IT (anti–PD-1)→ TT (ceritinib–trametinib or dabrafenib–trametinib) was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50b9bb63fd2da0db237760d414a79777
https://doi.org/10.1158/2326-6066.c.6550279
https://doi.org/10.1158/2326-6066.c.6550279
Autor:
Keiran S.M. Smalley, Paulo C. Rodriguez, Yian A. Chen, Christin E. Burd, Uwe Rix, Kenneth Y. Tsai, Kimberly T. Nguyen, Zeynep Eroglu, Dennis O. Adeegbe, David Noyes, Peter A. Forsyth, Brian J. Czerniecki, Vinayak Palve, Derek R. Duckett, Inna Smalley, Michael A. Davies, Eslam Mohamed, Jiannong Li, Zhihua Chen, Manali S. Phadke
S1: IT monotherapy in SW1 model S2: IT->dabrafenib-trametinib therapy in BRAF mutant melanoma. S3: IT->TT sequence in NRAS#5 model S4: Expanded heatmap of all immune cells S5: IT->TT increases accumulation of activated CD8+ T cells S6: The TT->IT seq
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00d2accefee1e50cca9f7a873ce9b54a
https://doi.org/10.1158/2326-6066.22543471
https://doi.org/10.1158/2326-6066.22543471
Autor:
David Noyes, Arup Bag, Saheed Oseni, Jon Semidey-Hurtado, Ling Cen, Amod A Sarnaik, Vernon K Sondak, Dennis Adeegbe
Publikováno v:
Journal for immunotherapy of cancer. 10(5)
BackgroundAccumulation of regulatory T cells (Treg) has been described to often correlate with poor prognosis in many solid tumors. How Treg presence impinges on limited functionality and clonal composition of tumor-associated CD8 +T cells has import
Autor:
Kenneth Y. Tsai, Yian A. Chen, Michael A. Davies, Derek R. Duckett, Brian J. Czerniecki, Inna Smalley, David Noyes, Zeynep Eroglu, Vinayak Palve, Jiannong Li, Keiran S.M. Smalley, K Nguyen, Paulo C. Rodriguez, Zhihua Chen, Peter A. Forsyth, Eslam Mohamed, Christin E. Burd, Uwe Rix, Dennis Adeegbe, Manali Phadke
Publikováno v:
Cancer Immunol Res
Immunotherapy and targeted therapy are both effective against melanoma, but their combination is frequently toxic. Here, we investigated whether the sequence of immunotherapy (IT; anti-PD1)->targeted therapy (TT; ceritinib-trametinib or dabrafenib-tr
Autor:
John Powers, Tuan P Nguyen, Mark B. Meads, Jason Brayer, David Noyes, Eduardo M. Sotomayor, William S. Dalton, Kenneth L. Wright, Maria D Coelho Siqueira Silva, Allison Distler, Gabriel De Avila, Hongyue A Dai, Eva Sahakian, Oliver A. Hampton, Kenneth H. Shain, Alexandre Tungesvik, John M. Koomen, Praneeth Reddy Sudalagunta, Amit Kulkarni, Raghunandan Reddy Alugubelli, A.G.M. Mostofa, Victoria Izumi, Bin Fang, Ariosto S. Silva, Javier Pinilla-Ibarz, Jamie K. Teer, Eric A. Welsh, Alexandra Achille, Gabriela Wright, Rupal Rampakrishnan, Rafael Renatino Canevarolo
Publikováno v:
JCI Insight
The clinical utility of histone/protein deacetylase (HDAC) inhibitors in combinatorial regimens with proteasome inhibitors for patients with relapsed and refractory multiple myeloma (MM) is often limited by excessive toxicity due to HDAC inhibitor pr
Autor:
David Noyes, Isabel L. Jackson, Theresa A. Boyle, Zeljko Vujaskovic, Kujtim Latifi, Scott J. Antonia, Bradford A. Perez, Derek Nichols, Vladimir Feygelman
Publikováno v:
Journal of Thoracic Disease. 10:6254-6260
Outcomes for patients with inoperable locally advanced non-small cell lung cancer (LA-NSCLC) are poor, with a median survival of about 2 years (1) and a 5-year survival of about 10–15% following diagnosis, even among patients with good performance
Autor:
Scott J. Antonia, Carmen M. Anadon, Xiaoqing Yu, Shari Pilon-Thomas, Eric B. Haura, Ana Marie Landin, David Noyes, John M. Koomen, Dongliang Du, Jose R. Conejo-Garcia, Chao Wang, Sungjune Kim, Jamie K. Teer, Ben C. Creelan, Jiqiang Yao, Bin Fang, Dung-Tsa Chen, Zachary J. Thompson
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Although cancer immunotherapies have achieved great success, many patients either do not respond or initially respond but later relapse. Several resistance mechanisms have been proposed from trials using immune checkpoint inhibitors or CAR